Melanotan I is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Melanotan I is one of the most discussed peptides in the research community, with reports focusing on its effects on skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning. Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
What Do Researchers Report About Melanotan I?
Melanotan I (Afamelanotide) is one of the most discussed Melanocortin-1 receptor (MC1R) agonist compounds in the peptide research community. Reports span effects on skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
What Are the Most Common Positive Reports?
Researchers frequently cite Melanotan I's effects on skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning as the primary benefits observed during standard cycles of 60-day implant cycles; 4-8 weeks injection cycles.
The only Melanotan analog with FDA approval and extensive Phase III clinical trial data — far better characterized for safety than the more popular (but more dangerous) Melanotan II. This distinctive profile is a key reason Melanotan I maintains its popularity despite the growing number of alternatives.
What Are the Common Criticisms?
The most common complaints about Melanotan I: Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
Cost and sourcing quality are also frequent concerns — results vary significantly between vendors, which is why COA testing is essential.
How Does Melanotan I Compare to Alternatives?
As a Melanocortin-1 receptor (MC1R) agonist, Melanotan I competes with several similar compounds. The only Melanotan analog with FDA approval and extensive Phase III clinical trial data — far better characterized for safety than the more popular (but more dangerous) Melanotan II.
Used as standalone; not typically combined with other melanocortin peptides.
Bottom Line: Is Melanotan I Worth It?
Based on the available research and community reports, Melanotan I is considered promising for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning. The key factors for success: consistent dosing (16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) every 60 days (implant) or daily (injection)), quality sourcing, and realistic expectations over 60-day implant cycles; 4-8 weeks injection cycles cycles.
Complete Guide
Melanotan I : Benefits, Dosage, Side Effects & Research
Related Reading
- Melanotan I Dosage Guide
- Melanotan I Benefits
- Melanotan I Side Effects
- Melanotan I Stacking Guide
- Melanotan I Cycle Guide
- Melanotan I Research
Calculate Your Melanotan I Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Melanotan I.
Open Calculator →Research-Grade Sourcing
If you're going to research Melanotan I, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Melanotan I?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation. It is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
What is the recommended Melanotan I dosage?
Common dosages: 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) via subcutaneous implant (approved) or subcutaneous injection. Cycle length: 60-day implant cycles; 4-8 weeks injection cycles. Half-life: ~2 hours circulating; implant provides 2-month depot release. Use our peptide calculator for exact reconstitution math.
What are the side effects of Melanotan I?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
Is Melanotan I safe?
Melanotan I has shown a preliminary safety profile in research. FDA-approved as Scenesse for EPP only (prescription). Not approved for cosmetic tanning. All research should follow appropriate safety protocols.